1. Home
  2. Directory
  3. Arizona
  4. Phoenix
  5. Student In An Organized Health Care Education Training Program
  6. NPI Profile
  7. Prescriptions 1598341521

DR. PETER QUANG MINH MAI MD
Prescription History 1598341521
Student in an Organized Health Care Education/Training Program in Phoenix, AZ

NPI Status: Active since March 21, 2021

Contact Information

350 W THOMAS RD
PHOENIX, AZ
ZIP 85013
Phone: (602) 406-6262
Fax: (602) 406-4606

Get Directions

Prescription History for Informed Healthcare Decisions

Explore the verified Medicare Part D prescription history, volume metrics, and calculated drug costs for DR. PETER QUANG MINH MAI MD, an active Student in an Organized Health Care Education/Training Program specialist practicing in Phoenix, AZ. Our medical registry currently tracks 4 unique pharmaceutical formulations prescribed by this provider, representing an estimated volume of 55 documented patient claims. Among these therapy options, the most frequently utilized medication is Levetiracetam, which accounts for 17 claims alone.

Medication Index

G
L
Z
No matching medications currently found on file.

Gabapentin

Generic Formulation: GabapentinSpecialty: Student in an Organized Health Care Education/Training Program
Provider Metrics Summary
Total Claims 14
30-Day Fills 15.5
Days Supply 465
AZ State Average Benchmarks
Peer Average Claims84.0
Peer Average 30-Day Fills145.0
Peer Average Days Supply4,266
Highly Conservative Utilization

This provider demonstrates a highly selective approach to this formula, recording 83.3% less volume than the regional standard for practitioners inside AZ. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $222.63 across this reporting matrix range.

Provider Avg Cost Per Claim

$15.90

State Avg Cost Per Claim

$23.55

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A cyclohexane-gamma-aminobutyric acid derivative that is used for the treatment of PARTIAL SEIZURES; NEURALGIA; and RESTLESS LEGS SYNDROME.

Therapeutic Applications

Gabapentin is used with other medications to prevent and control seizures. It is also used to relieve nerve pain following shingles (a painful rash due to herpes zoster infection) in adults. Gabapentin is known as an anticonvulsant or antiepileptic drug.

Lamotrigine

Generic Formulation: LamotrigineSpecialty: Student in an Organized Health Care Education/Training Program
Provider Metrics Summary
Total Claims 11
30-Day Fills 11.0
Days Supply 305
AZ State Average Benchmarks
Peer Average Claims54.0
Peer Average 30-Day Fills85.8
Peer Average Days Supply2,500
Highly Conservative Utilization

This provider demonstrates a highly selective approach to this formula, recording 79.6% less volume than the regional standard for practitioners inside AZ. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $276.33 across this reporting matrix range.

Provider Avg Cost Per Claim

$25.12

State Avg Cost Per Claim

$17.12

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A phenyltriazine compound, sodium and calcium channel blocker that is used for the treatment of SEIZURES and BIPOLAR DISORDER.

Therapeutic Applications

Lamotrigine is used alone or with other medications to prevent and control seizures. It may also be used to help prevent the extreme mood swings of bipolar disorder in adults. Lamotrigine is known as an anticonvulsant or antiepileptic drug. It is thought to work by restoring the balance of certain natural substances in the brain. This drug is not approved for use in children younger than 2 years due to an increased risk of side effects (such as infections).

Levetiracetam

Generic Formulation: LevetiracetamSpecialty: Student in an Organized Health Care Education/Training Program
Provider Metrics Summary
Total Claims 17
30-Day Fills 37.0
Days Supply 1,110
AZ State Average Benchmarks
Peer Average Claims44.0
Peer Average 30-Day Fills76.2
Peer Average Days Supply2,214
Highly Conservative Utilization

This provider demonstrates a highly selective approach to this formula, recording 61.4% less volume than the regional standard for practitioners inside AZ. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $995.51 across this reporting matrix range.

Provider Avg Cost Per Claim

$58.56

State Avg Cost Per Claim

$45.21

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A pyrrolidinone and acetamide derivative that is used primarily for the treatment of SEIZURES and some movement disorders, and as a nootropic agent.

Therapeutic Applications

Levetiracetam is used to treat seizures (epilepsy). It belongs to a class of drugs known as anticonvulsants. Levetiracetam may decrease the number of seizures you have.

Zonisamide

Generic Formulation: ZonisamideSpecialty: Student in an Organized Health Care Education/Training Program
Provider Metrics Summary
Total Claims 13
30-Day Fills 25.0
Days Supply 734
AZ State Average Benchmarks
Peer Average Claims35.0
Peer Average 30-Day Fills61.4
Peer Average Days Supply1,806
Highly Conservative Utilization

This provider demonstrates a highly selective approach to this formula, recording 62.9% less volume than the regional standard for practitioners inside AZ. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $670.31 across this reporting matrix range.

Provider Avg Cost Per Claim

$51.56

State Avg Cost Per Claim

$54.70

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A benzisoxazole and sulfonamide derivative that acts as a CALCIUM CHANNEL blocker. It is used primarily as an adjunctive antiepileptic agent for the treatment of PARTIAL SEIZURES, with or without secondary generalization.

Therapeutic Applications

Zonisamide is used with other medications to prevent and control seizures (epilepsy). Zonisamide is a sulfonamide anticonvulsant and a carbonic anhydrase inhibitor. It is unknown how zonisamide works to prevent seizures.

Dataset Methodology & CMS Source Information

This analytical profile maps public infrastructure records sourced directly from official **Centers for Medicare & Medicaid Services (CMS)** public data releases. The statistics above track documented pharmaceutical treatment trends assigned to beneficiaries specifically under federal public programs. Evaluating the prescriptive footprints of clinical practitioners like DR. PETER QUANG MINH MAI MD provides transparency into local medical care patterns within Phoenix, AZ.

Key Learning Objectives for this Profile:

  • Prescribing Frequencies: Track and evaluate the volume metrics of specific brand-name and generic medical formulas chosen by this provider over time.
  • Clinical Focus Areas: Identify how the provider distributes therapeutic selections across medical care options to gain insight into their true day-to-day **Student in an Organized Health Care Education/Training Program** practice concentrations.
  • Program Cost Awareness: Review the calculated total systemic drug costs and raw transactional volumes linked to these orders to better anticipate network insurance coverage structures.
  • Patient-Centered Evaluation: Cross-reference localized regional care comparisons to align practitioner habits directly with your proactive health maintenance goals.

Data Scope Exclusion & Limitations: The data elements presented above explicitly reflect prescription orders processed for Medicare beneficiaries during the year 2023. This informational profile does not aggregate prescription data for individuals utilizing private commercial health plans, state Medicaid coverage, or self-pay options. However, because medical decision-making remains highly consistent across clinical settings, this public registry provides a reliable proxy for understanding the general prescribing preferences and pharmaceutical care approach used by this provider.